Reshma Kewalramani - 15 Aug 2022 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
CEO & President, Director
Signature
/s/ Joy Liu, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
15 Aug 2022
Net transactions value
-$3,565,846
Form type
4
Filing time
17 Aug 2022, 17:40:28 UTC
Previous filing
21 Jul 2022
Next filing
10 Nov 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Sale $3,565,846 -11,689 -11% $305.06 99,598 15 Aug 2022 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1.
F2 Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $305.06 (range $305.00 to $305.22).